Targeting RAS–RAF–MEK–ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework

International Journal of Gynecological Cancer 2026 Open access

Read full text
Authors: Thomas Bartl, Dan Cacsire Castillo-Tong
DOI: 10.1016/j.ijgc.2026.104485
Cited by: 1
References: 60

Abstract

Mucinous ovarian cancer is a rare and molecularly distinct sub-type of epithelial ovarian cancer, characterized by intrinsic resistance to cytotoxic chemotherapy and poor prognosis in advanced stages, with a median overall survival of 12 to 34 months. Its low incidence (

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Melanoma and MAPK Pathways PARP inhibition in cancer therapy

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
4
Pages
104485–104485
Publication date
10 January 2026
Language
EN